Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Common Equity (2020 - 2025)

Foghorn Therapeutics has reported Common Equity over the past 6 years, most recently at -$108.5 million for Q4 2025.

  • Quarterly results put Common Equity at -$108.5 million for Q4 2025, down 138.31% from a year ago — trailing twelve months through Dec 2025 was -$108.5 million (down 138.31% YoY), and the annual figure for FY2025 was -$108.5 million, down 138.31%.
  • Common Equity for Q4 2025 was -$108.5 million at Foghorn Therapeutics, down from -$89.7 million in the prior quarter.
  • Over the last five years, Common Equity for FHTX hit a ceiling of $125.2 million in Q1 2021 and a floor of -$108.5 million in Q4 2025.
  • Median Common Equity over the past 5 years was -$26.4 million (2023), compared with a mean of -$8.9 million.
  • Biggest five-year swings in Common Equity: soared 223.67% in 2021 and later crashed 69019.64% in 2023.
  • Foghorn Therapeutics' Common Equity stood at $96.9 million in 2021, then tumbled by 99.88% to $112000.0 in 2022, then crashed by 69019.64% to -$77.2 million in 2023, then soared by 41.02% to -$45.5 million in 2024, then plummeted by 138.31% to -$108.5 million in 2025.
  • The last three reported values for Common Equity were -$108.5 million (Q4 2025), -$89.7 million (Q3 2025), and -$76.7 million (Q2 2025) per Business Quant data.